| Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions. | |
| | |
MedLine Citation:
|
PMID: 18039918 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Resiquimod, a Toll-like receptor 7/8 agonist developed as a topical treatment to decrease recurrences of anogenital herpes, induces proinflammatory cytokines that may delay lesion healing. Adults with frequently recurring anogenital herpes were randomized within 24 h of onset of a recurrence to vehicle or resiquimod 0.01% gel two times per week for 3 weeks. Subjects underwent daily lesion assessments and sampling for herpes simplex virus DNA PCR for 21 days or until investigator-determined healing of lesion(s). Eighty-two subjects with a mean age of 39 +/- 10.5 years and a median of seven recurrences per year were enrolled in the study. The qualifying recurrence was positive by PCR for herpes simplex virus in 68% of subjects. No difference was observed between the vehicle (39 subjects) and resiquimod (43 subjects) groups with respect to time to healing (median of 7.0 days versus median of 6.5 days, respectively; Cox proportional hazard model ratio of 1.229; 95% confidence interval, 0.778 to 1.942; P = 0.376). The distributions of maximum severity scores for any investigator-assessed local skin signs and for subject-assessed local symptoms were similar between treatment groups (P = 0.807 and P = 0.103, respectively). For subjects with at least one positive PCR result, no difference was observed for time to cessation of viral shedding (median of 7 days versus median of 5 days for vehicle and resiquimod groups, respectively; Cox proportional hazard model ratio of 1.471; 95% confidence interval, 0.786 to 2.754; P = 0.227). Application of resiquimod 0.01% two times per week for 3 weeks did not delay the healing of genital herpes lesions or reduce acute viral shedding. |
| | |
Authors:
|
Kenneth H Fife; Tze-Chiang Meng; Daron G Ferris; Ping Liu |
Related Documents
:
|
16885778 - Survival rate and risk factors of mortality among hiv/tuberculosis-coinfected patients ... 9487448 - A controlled clinical trial of oral short-course regimens in the treatment of sputum-po... 20952898 - Managing recurrent genital herpes with acyclovir. 20023248 - A clinical pilot study of lignin--ascorbic acid combination treatment of herpes simplex... 18705948 - The basilar artery international cooperation study (basics). 19139778 - Dexmedetomidine as a substitute for remifentanil in ambulatory gynecologic laparoscopic... |
Publication Detail:
|
Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2007-11-26 |
Journal Detail:
|
Title: Antimicrobial agents and chemotherapy Volume: 52 ISSN: 0066-4804 ISO Abbreviation: Antimicrob. Agents Chemother. Publication Date: 2008 Feb |
Date Detail:
|
Created Date: 2008-01-24 Completed Date: 2008-04-29 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 0315061 Medline TA: Antimicrob Agents Chemother Country: United States |
Other Details:
|
Languages: eng Pagination: 477-82 Citation Subset: IM |
Affiliation:
|
Division of Infectious Diseases, Departmernt of Medicine, Indiana University School of Medicine, Emerson Hall 435, 545 Barnhill Drive, Indianapolis, IN 46202, USA. kfife@iupui.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Topical Adult Aged Antiviral Agents* / administration & dosage, pharmacology, therapeutic use Double-Blind Method Female Herpes Genitalis / drug therapy*, virology Herpesvirus 2, Human / drug effects, genetics, isolation & purification, physiology Humans Imidazoles* / administration & dosage, pharmacology, therapeutic use Male Middle Aged Proportional Hazards Models Time Factors Treatment Outcome Virus Shedding / drug effects* Wound Healing / drug effects* |
| Chemical | |
Reg. No./Substance:
|
0/Antiviral Agents; 0/Imidazoles; 0/R 848 |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Novel chimeric genotype 1b/2a hepatitis C virus suitable for high-throughput screening.
Next Document: In vitro antifungal susceptibilities of five species of sporothrix.